Vibecotamab

• CAT Number: I042133
• CAS Number: 2138442-13-2
• Purity: ≥95%

Vibecotamab (Cat No.:I042133) is an investigational bispecific antibody developed by AbbVie that targets both the PD-1 (Programmed cell death protein 1) and the 4-1BB receptor, which plays a role in enhancing immune responses. By engaging both immune checkpoints, Vibecotamab is designed to stimulate anti-tumor immunity more effectively than therapies targeting PD-1 alone. It aims to improve immune cell activation and tumor cell destruction. Vibecotamab is being tested in clinical trials for various cancers, including solid tumors, with the goal of providing a more potent treatment for patients with advanced disease.